Clinical Trial

A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events (MAKE) in approximately 50 participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-08.
Trial Details
NCT Number NCT07164833
Lead Sponsor Bilix Co.,Ltd.
Conditions Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury
Enrollment 50 participants
Start Date 2025-08-26
Primary Completion 2027-09 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-01